-=Kura Oncology (KURA) :

Rises to its highest levels since December on above 9x average volume, posting gains alongside its peer in the cancer treatments development space, Syndax Pharmaceuticals (SNDX); co's pipeline includes a menin-MLL inhibitor, KO-539.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 57
• Founded in 2014 
• HQ inSan Diego, California
• http://www.kuraoncology.com

-=Syndax Pharmaceuticals (SNDX) : initial data for SNDX-5613

• Announced positive early-stage data on candidate SNDX-5613, a small molecule inhibitor designed to block the interaction between a tumor suppressor protein called menin and another protein called MLL that plays a key role in the development of acute leukemia. 
• Kura also has a menin-MLL inhibitor in development, KO-539, currently in Phase 1/2 development.
• Price target raised to $33 from $27 at Baird. 
• Surged to all-time highs.

Ticker:  SNDX

Syndax Pharmaceuticals presents preclinical and initial data for SNDX-5613 in adults with relapsed/refractory acute leukemias 

Syndax Pharmaceuticals today presents preclinical and initial clinical data for SNDX-5613, the company's potent, highly selective oral menin inhibitor. The oral presentation will be featured during the New Drugs on the Horizon session at the 2020 AACR Virtual Annual Meeting I.

• As of the April 17 data cutoff date, a total of six patients have been treated in the Phase 1 portion of the ongoing open-label AUGMENT-101 trial at increasing dose levels of SNDX-5613. Responses were observed in two of three patients harboring an MLL rearrangement. This included one patient, whose drug exposure was consistent with that needed for activity in preclinical models, who had a complete response with incomplete blood count recovery (CRi) after 28 days of therapy and subsequently improved to a complete response (CR). The second patient achieved a partial response with incomplete blood count recovery (PRi) after 28 days of therapy. Both patients continue to receive SNDX-5613. A third patient harboring an MLL rearrangement did not achieve drug exposure levels consistent with that needed for activity in preclinical models and was removed from the trial due to progressive disease.
• Treatment with SNDX-5613 has been tolerated well, with no dose limiting toxicities reported. One patient experienced a Grade 2 QTc prolongation but remains on treatment.

The company also announced today that SNDX-5613 was recently granted Orphan Drug Designation for the treatment of adult and pediatric acute myeloid leukemia by the FDA.

Syndax Pharmaceuticals (SNDX) began trading on Nasdaq on 3 March 2016

• Syndax Pharmaceuticals is a cancer-focused biotechnology company.
• IPO issue price of $12.
• Syndax sold 4.4 million shares to raise $52.8 million. 
• The company had previously set a price range of $14 to $16. Morgan Stanley, Citigroup, JMP Securities and Oppenheimer were the underwriters for the offering.

Ticker:  SNDX

monthly; Dec 2016; 9 months after IPO

March 2017; 1 year after IPO

Description

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Address

400 Totten Pond Rd Ste 110
WALTHAM, MA 02451-2040
United States 

Key stats and ratios

	Q4 (Dec '16)	2016
Net profit margin	-3545.90%	-3645.25%
Operating margin	-3652.79%	-3587.38%
EBITD margin	-	-3580.08%
Return on average assets	-38.26%	-44.71%
Return on average equity	-48.75%	-
Employees	17